Digene (now merged with QIAGEN)

Industry:	Medical Testing & Clinical Laboratories
Ranking:	Russell 3000
Revenues:	$152.9 Million
Employees:	490

Description

By merging with Digene, QIAGEN now also develops, manufactures and markets proprietary DNA and RNA tests focused on women's cancers and infectious diseases. The Digene® HPV Test is the only FDA-approved test for the human papillomavirus (HPV), the cause of cervical cancer. Rapidly emerging as a standard of practice in cervical cancer screening, the HPV test aids healthcare professionals in identifying women who are most at risk of having or developing cervical cancer, which today is the world's second-most-common type of cancer affecting women.

QIAGEN employs more than 2,000 people worldwide. Our products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. QIAGEN's customer satisfaction department focuses on continually exceeding our customers' increasing expectations.

Products & Services

testing systems, molecular diagnostics

View More Statistics

Site Statistics

Monthly Unique Visitors:	22,210
Site Rank:	77,688
Trust Rating:	Trusted
Stats by